41807-65-2Relevant academic research and scientific papers
Novel anti-tuberculosis agents from MCR libraries
Doemling, Alexander,Achatz, Sepp,Beck, Barbara
, p. 5483 - 5486 (2007)
Structure-based design of libraries of multi-component reaction products yields novel potent anti-tuberculosis compounds. Synthesis and preliminary biological results are presented.
Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists
He, Shuwen,Dobbelaar, Peter H.,Liu, Jian,Jian, Tianying,Sebhat, Iyassu K.,Lin, Linus S.,Goodman, Allan,Guo, Cheng,Guzzo, Peter R.,Hadden, Mark,Henderson, Alan J.,Ruenz, Megan,Sargent, Bruce J.,Yet, Larry,Kelly, Theresa M.,Palyha, Oksana,Kan, Yanqing,Pan, Jie,Chen, Howard,Marsh, Donald J.,Shearman, Lauren P.,Strack, Alison M.,Metzger, Joseph M.,Feighner, Scott D.,Tan, Carina,Howard, Andrew D.,Tamvakopoulos, Constantin,Peng, Qianping,Guan, Xiao-Ming,Reitman, Marc L.,Patchett, Arthur A.,Wyvratt Jr., Matthew J.,Nargund, Ravi P.
scheme or table, p. 1913 - 1917 (2010/07/02)
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.
